MedTrace Logo

A Safety and Pharmacokinetic Study of Proellex®

NCT00619385 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-08-08

Study results available
· View outcomes & findings →

Summary

Dose escalating study of 7 daily doses of Proellex at 100 mg, 150 mg and 200 mg

Conditions

  • Healthy

Interventions

DRUG

Proellex

Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days

Sponsors & Collaborators

  • Repros Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Andre van As, MD, PhD · Repros Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-09-30
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619385 on ClinicalTrials.gov